Table 5. . Randomized clinical trials of targeted therapies in colorectal cancer.
| Target | Study | Treatment | Median OS or PFS | HR (95% CI) | Ref. |
|---|---|---|---|---|---|
| VEGF-A |
AVF2107g trial (NCT00109070) |
IFL (n = 411) IFL + bevacizumab (n = 402) |
OS: 20.3 OS: 15.6 |
0.66 |
[69] |
| VEGF-A |
NO16966 trial (NCT00069095) |
Oxaliplatin-based (n = 700) Oxaliplatin-based + bevacizumab (n = 701) |
OS: 21.3 OS: 19.9 |
0.89 (0.76–1.03) |
[70] |
| EGFR (KRAS wild-type) |
CRYSTAL (NCT00154102) |
FOLFIRI (n = 176) FOLFIRI + cetuximab (n = 172) |
PFS: 8.7 PFS: 9.9 |
0.68 (0.50–0.94) |
[4] |
| VEGF-A/EGFR (KRAS wild-type) |
PEAK (NCT00819780) |
FOLFOX + bevacizumab (n = 143) FOLFOX + panitumumab (n = 142) |
OS: 24.3 OS: 34.2 |
0.62 (0.44–0.89) |
[71] |
| VEGF-A/EGFR (KRAS wild-type) |
FIRE-3 (NCT00433927) |
FOLFIRI + bevacizumab (n = 171) FOLFIRI + cetuximab (n = 171) |
OS: 25.6 OS: 33.1 |
0.70 (0.53–0.92) |
[72] |
| VEGF-A/EGFR (KRAS wild-type) |
CALGB/SWOG 80405 (NCT00265850) |
Chemotherapy + bevacizumab (n = 559) Chemotherapy + cetuximab (n = 578) |
OS: 29.0 OS: 29.9 |
0.92 (0.78–1.09) |
[73] |
| VEGF-A and EGFR |
PACCE (NCT00115765) |
CT + bevacizumab (n = 525) CT + bevacizumab + panitumumab (n = 528) |
PFS: 11.4 PFS: 10.0 |
1.27 (1.06–1.52) |
[74] |
| Multikinase | CORRECT (NCT01103323) | Placebo (n = 255) Regorafenib (n = 505) |
OS: 5.0 OS: 6.4 |
0.77 (0.64–0.94) | [75] |
CT: Chemotherapy;FOLFIRI: Fluorouracil, folinic acid and irinotecan; FOLFOX: Fluorouracil, folinic acid and L-OHP; HR: Hazard ratio; IFL: Irinotecan, folinic acid and fluorouracil; OS: Overall survival; PFS: Progression-free survival.